Are you Dr. Ali?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 73 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1700 S Lincoln Ave
Lebanon Vamc
Lebanon, PA 17042Phone+1 717-272-6621Fax+1 717-228-6118- Is this information wrong?
Summary
- Dr. Suhail Ali, MD is an oncologist in Lebanon, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania and Michigan. He is affiliated with Lebanon Veterans Affairs Medical Center.
Education & Training
- Geisinger Health SystemFellowship, Hematology and Medical Oncology, 1997 - 1998
- Washington University/B-JH/SLCH ConsortiumFellowship, Blood Banking/Transfusion Medicine, 1995 - 1997
- Henry Ford HospitalResidency, Internal Medicine, 1992 - 1994
- Westchester Medical CenterInternship, Internal Medicine, 1991 - 1992
- Dow University of Health SciencesClass of 1988
Certifications & Licensure
- PA State Medical License 1997 - 2024
- MI State Medical License 1993 - 2006
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 11 citationsFibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types.Nicholas Willumsen, Christina Jensen, George Green, Neel I Nissen, Jaclyn Neely, David M Nelson, Rasmus S Pedersen, Peder Frederiksen, Inna M Chen, Mogens K Boisen, As...> ;Cellular and Molecular Life Sciences. 2022 Mar 25
- 5 citationsCellular Fitness Phenotypes of Cancer Target Genes from Oncobiology to Cancer TherapeuticsBijesh George, P. Mukundan Pillai, Aswathy Mary Paul, Revikumar Amjesh, Kim Leitzel, Suhail M. Ali, Oleta A. Sandiford, Allan Lipton, Pranela Rameshwar, Gabriel N. Hor...> ;Cells. 2021 Feb 18
- 4 citationsHigher serum PD-L1 level predicts increased overall survival with lapatinib versus trastuzumab in the CCTG MA.31 phase 3 trial.Prashanth Reddy Moku, Lois E. Shepherd, Suhail M. Ali, Kim Leitzel, Wendy R. Parulekar, Liting Zhu, Shakeel Virk, Dora Nomikos, Samuel Aparicio, Karen A. Gelmon, Josep...> ;Cancer. 2020 Nov 15
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- Lebanon Veterans Affairs Medical CenterLebanon, Pennsylvania